GLPG vs LLY vs PFE vs BMY vs ABBV

For growth investors, Galapagos N.

V. (GLPG) is the stronger pick with 303. 5% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Galapagos N. V. (GLPG) offers the better valuation at 5. 0x trailing P/E, making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Galapagos N.

V. (GLPG) is the cheapest at 5. 0x versus AbbVie Inc. at 85. 0x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +399.

3%, compared to -61. 1% for Galapagos N. V. (GLPG). Over 10 years, the gap is even starker: LLY returned +1203% versus GLPG's -40. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 28β versus Galapagos N. V. 's 0. 74β — meaning GLPG is approximately 168% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Galapagos N. V. (GLPG) carries a lower debt/equity ratio of 0% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Galapagos N.

V. (GLPG) is pulling ahead at 303. 5% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Galapagos N. V. grew EPS 333. 0% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, GLPG leads at 66. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus 6. 9% for AbbVie Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 24. 7% for PFE. At the gross margin level — before operating expenses — GLPG leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 8. 7x forward P/E versus 26. 3x for Eli Lilly and Company — 17. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LLY: 33. 0% to $1261. 11.

In this comparison, PFE (6.

7% yield), BMY (4. 4% yield), ABBV (3. 3% yield), LLY (0. 6% yield) pay a dividend. GLPG does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65), 0. 6% yield, +1203% 10Y return). Both have compounded well over 10 years (LLY: +1203%, GLPG: -40. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GLPG is a small-cap high-growth stock; LLY is a large-cap high-growth stock; PFE is a mid-cap income-oriented stock; BMY is a mid-cap deep-value stock; ABBV is a large-cap income-oriented stock. LLY, PFE, BMY, ABBV pay a dividend while GLPG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.